Amgen Can't Stop Avastin Biosimilar 'Patent Dance' After Opting In, Genentech Says
Executive Summary
Genentech seeks court order requiring Amgen to provide biosimilar manufacturing info so it can evaluate potential infringement; Supreme Court to hear Zarxio case on April 26.